UK's regulatory and legislative double standards in the treatment of psychedelics and drugs for assisted suicide.

Abstract

This editorial highlights the UK's drug regulatory double standards. Drugs for assisted suicide would bypass standard regulation despite limited evidence, while psychedelics face significant barriers despite promising evidence internationally. I argue that drugs for assisted suicide should meet the same regulatory standards, and psychedelics should be rescheduled to enable further clinical research.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

Keywords